Loading clinical trials...
Loading clinical trials...
A Randomised, Double-blind, Phase III Study to Compare the Efficacy and Safety of Cediranib (AZD2171, RECENTIN™) When Added to 5 Fluorouracil, Leucovorin and Oxaliplatin (FOLFOX) or Capecitabine and Oxaliplatin (XELOX) With the Efficacy and Safety of Placebo When Added to FOLFOX or XELOX in Patients With Previously Untreated Metastatic Colorectal Cancer.
Conditions
Interventions
Cediranib
FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
+2 more
Locations
90
Argentina
Research Site
Buenos Aires, Argentina
Research Site
Capital Federal, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
Córdoba, Argentina
Research Site
Resistencia, Argentina
Research Site
Rosario, Argentina
Start Date
November 1, 2006
Primary Completion Date
March 1, 2010
Completion Date
August 1, 2016
Last Updated
December 28, 2016
NCT04657068
NCT06625775
NCT06607458
NCT06820463
NCT07361003
NCT06792695
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions